MATERIALS AND METHODSReview Questio

MATERIALS AND METHODS
Review Question
The review question was to what extent BMSC transplantation in combination
with CABG affects left ventricular function in patients with
chronic ischemic heart disease compared with CABG alone.
Eligibility Criteria
Two reviewers (P.D and A.K.) judged the eligibility of studies in duplicate
and independently. Eligible trials had to fulfill the following criteria:
RCTs or cohort study design comparing routine surgical treatment of
chronic ischemic heart disease by CABG with treatment by intramyocardial
BMSC injection in addition to CABG; minimum of 3-month followup
after stem cell therapy; and intramyocardial injection of BMSCs into
ischemic area. Exclusion criteria were intracoronary stem cell injection
and catheter-based injection methods; stem cell injection without CABG;
treatment of acute myocardial infarction; RCTs and cohort studies with
incomplete left ventricular ejection fraction (LVEF) data; and stem or progenitor
cells derived from other sources than bone marrow.
Search Strategy
To identify relevant studies, the electronic databases PUBMED, MEDLINE,
Cochrane Controlled Trials Register, and ClinicalTrials (all from
their inception to May 2009) were searched with the following databaseappropriate
terms: bone marrow, stem cells, progenitor cells, intramyocardial,
coronary artery bypass surgery, CABG, transplantation, and trial.
Language restrictions were not imposed. Reference lists of identified articles
and relevant review articles on the topic were also reviewed. Finally,
the included articles were limited to English description, and articles on animal
experiments were excluded.
Data Abstraction
Two reviewers (P.D. and A.K.) independently assessed included studies
according to author of the study, year of publication, geographic location of
the study, study type, study population, follow-up period, treatment
group, control group, LVEF at baseline (LVEFbaseline) and follow-up
(LVEFfollow-up), LVEF change from baseline to follow-up for the treatment
(LVEFBMSC change) and the control group (LVEFcontrol change), left ventricular
end-diastolic volume at baseline (LVEDVbaseline) and follow-up
(LVEDVfollow-up), and LVEDV change from baseline to follow-up. Moreover,
the number of bypass grafts performed, number of ischemic/akinetic
territories, target areas of cell injection, and timing of CABG with combined
cell therapy after infarction were assessed (Tables 1–4). The major
adverse cardiovascular events (MACE) (Table 5) include ventricular
arrhythmias and the composite of other serious cardiovascular events
(cardiac death, recurrent myocardial infarction, additional coronary revascularization
procedures, and stroke). Relevant data were extracted from the
included articles, put into tables, and combined according to the composite
outcome definition.

Hasil (Bahasa Indonesia) 1:

BAHAN DAN METODEPertanyaan TinjauanPertanyaannya review adalah sejauh BMSC transplantasi dalam kombinasidengan CABG mempengaruhi fungsi ventrikel kiri pada pasien dengankronis penyakit jantung iskemik dibandingkan dengan CABG sendirian.Kriteria kelayakanDua penelaah (P.D dan A.K.) dinilai kelayakan studi di duplikatdan mandiri. Uji yang memenuhi syarat harus memenuhi kriteria sebagai berikut:RCTs atau kelompok belajar desain membandingkan rutin perawatan bedahkronis penyakit jantung iskemik oleh CABG dengan perawatan oleh intramyocardialBMSC injeksi selain CABG; minimal 3 bulan ikutansetelah terapi sel induk; dan injeksi intramyocardial BMSCs kedaerah iskemik. Kriteria pengecualian yang intracoronary sel induk injeksidan metode berbasis kateter injeksi; injeksi sel induk tanpa CABG;pengobatan infark miokard akut; RCTs dan Studi kohort dengandata yang tidak lengkap ejeksi ventrikel kiri sebagian kecil (LVEF); dan batang atau leluhursel-sel yang berasal dari sumber-sumber lain dari sumsum tulang.Strategi pencarianUntuk mengidentifikasi studi yang relevan, database elektronik PUBMED, MEDLINE,Cochrane Controlled uji mendaftar, dan ClinicalTrials (semua dariawal-Mei 2009) yang dicari dengan databaseappropriate berikutSyarat: sumsum tulang, sel-sel induk, nenek moyang sel, intramyocardial,bedah bypass arteri koroner, CABG, transplantasi dan percobaan.Bahasa pembatasan tidak dipaksakan. Daftar referensi diidentifikasi artikeland relevant review articles on the topic were also reviewed. Finally,the included articles were limited to English description, and articles on animalexperiments were excluded.Data AbstractionTwo reviewers (P.D. and A.K.) independently assessed included studiesaccording to author of the study, year of publication, geographic location ofthe study, study type, study population, follow-up period, treatmentgroup, control group, LVEF at baseline (LVEFbaseline) and follow-up(LVEFfollow-up), LVEF change from baseline to follow-up for the treatment(LVEFBMSC change) and the control group (LVEFcontrol change), left ventricularend-diastolic volume at baseline (LVEDVbaseline) and follow-up(LVEDVfollow-up), and LVEDV change from baseline to follow-up. Moreover,the number of bypass grafts performed, number of ischemic/akineticterritories, target areas of cell injection, and timing of CABG with combinedcell therapy after infarction were assessed (Tables 1–4). The majoradverse cardiovascular events (MACE) (Table 5) include ventriculararrhythmias and the composite of other serious cardiovascular events(cardiac death, recurrent myocardial infarction, additional coronary revascularizationprocedures, and stroke). Relevant data were extracted from theincluded articles, put into tables, and combined according to the compositeoutcome definition.